Implementation and evaluation of the effectivity of an inpatient smoking cessation therapy by a mobile applicable therapy team

Implementation and evaluation of the effectivity of an inpatient smoking cessation therapy by a mobile applicable therapy team - START

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013466

Enrollment

458

Registered

2019-04-01

Start date

2019-01-23

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F17.2

Interventions

Group 1: Intervention group: inpatient 9-day behavior-therapeutic smoking cessation in groups (~ 9 hours of therapy) at the Breisgau-Klinik Bad Krozingen, accompanied by supportive interventions (nutr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 18 years smoking of at least 10 cigarettes per day motivation to stop smoking by participating in a group therapy analogous to "Nichtraucher in 6 Wochen"

Exclusion criteria

Exclusion criteria: Mental disorders that require treatment, alcohol consumption >2 beer or 1/2l wine per day (half the amount for women), substance abuse (anamnestic), insufficient German language skills, pregnancy, serious medical conditions that interfere with the ability to participate at the study, especially diseases with a life expectancy < 12 months. participation in programms for smoking cessation in the intervention period (incl. hypnosis, telefone consultation, acupuncture).

Design outcomes

Primary

Measure	Time frame
Comparison of constant tobacco abstinence after 6 and 12 months in both groups.	—

Secondary

Measure	Time frame
7-day point abstinence after 6 and 12 months (incl. cotinin-assessment for biovalidation), smoking status after completing the therapy, use of nicotine replacement therapies/medication, number and reasons for discontinuation of therapy, reasons for relapses, date of smoking the first cigarette, number of cigarettes and days smoking, number and duration of attempts to regain abstinence, change of the degree of smoking dependence with the FTND (Bleich et al., 2002) at relapse, self-efficacy expectation for tobacco abstinence (SER; Jäkle et al., 1999), motivation and volition for tobacco abstinence, according to the HAPA-Model (Schwarzer et al., 2008), cost-effectiveness analysis (QALYS by EQ-5D-5L; EuroQol Group, 2009), weight progression with a weighing protocol, side effects, adverse events (e.g. sleep disturbance, depression [PHQ-9, Löwe et al., 2002])	—

Measure

Time frame

7-day point abstinence after 6 and 12 months (incl. cotinin-assessment for biovalidation), smoking status after completing the therapy, use of nicotine replacement therapies/medication, number and reasons for discontinuation of therapy, reasons for relapses, date of smoking the first cigarette, number of cigarettes and days smoking, number and duration of attempts to regain abstinence, change of the degree of smoking dependence with the FTND (Bleich et al., 2002) at relapse, self-efficacy expectation for tobacco abstinence (SER; Jäkle et al., 1999), motivation and volition for tobacco abstinence, according to the HAPA-Model (Schwarzer et al., 2008), cost-effectiveness analysis (QALYS by EQ-5D-5L; EuroQol Group, 2009), weight progression with a weighing protocol, side effects, adverse events (e.g. sleep disturbance, depression [PHQ-9, Löwe et al., 2002])

—

Countries

Germany

Contacts

Public ContactPräventionsteam – CPMT START-Studie

Universitätsklinikum Freiburg

cpmt@uniklinik-freiburg.de+49 761 270-36070

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026